Finally, regarding SCLC subtypes, NEUROD1 and POU2F3 antibodies might not be ideal for immunoblotting and it was difficult to define which subtype marker was dominantly positive in the TMA study, partially due to multiple positives or no positives. This evidence concerns the gene NEUROD1 and small cell lung carcinoma.